These drugs, acting as agonists of Glucagon-like Peptide-1 receptor (GLP-1R), are recognized for promoting insulin secretion, suppressing glucagon release, and delaying gastric emptying [1]. However, while the beneficial effects of GLP-1 RAs on glycemic control, weight loss, and blood pressure reduction are extensively documented, a crucial aspect requiring further investigation is their impact on thyroid function.
Compared with placebo or other interventions, GLP-1 receptor agonists use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60). However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI ...
- Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. ... Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents. ... Effect of exendin (exenatide)GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.
- Use of GLP-1 RA for 13 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.271.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.043.05).
- The authors found that while rodent ... cancer, the best available human evidence did not demonstrate that GLP-1 receptor agonists caused common thyroid cancers or adversely affected existing thyroid malignancies....
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonist Side Effects Thyroid.
- New Rochelle, NY, new study found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer.
- There have been several studies ... of GLP-1 agonists vs. a non-GLP-1 agonist show that overall, thyroid cancer is increased in people who take GLP-1s....
